Health Care Retreats as Danaher Offsets Drug Distributor Gains

In the Health Care sector, 53.6% of the graded weight in the Health Care Select Sector SPDR Fund (Health Care Select Sector SPDR Fund), an exchange-traded fund trading under the ticker XLV, sits in companies graded A or B against their industry peers. On Thursday, October 1, market participation was narrow, with only 16.1% of the sector's S&P 500 members advancing. The sector closed -1.3% on a cap-weighted basis, compared with -1.1% for the equal-weighted measure, showing that larger components exerted greater downward pressure. Weakness was centered in life sciences equipment maker Danaher Corporation, which finished -4.4%, offsetting gains among pharmaceutical distributors where McKesson Corporation closed +5.4% and Cencora Inc. ended +3.2%. Sector sentiment retreated as swings in Treasury yields pressured defensive and high-multiple equities across the market.

The steepest drag among individual names came from Danaher Corporation. The company announced that Julie Sawyer Montgomery formally assumed the role of president and chief executive officer, effective October 1. The executive transition left Danaher Corporation as the primary drag on the sector index.

Pharmaceutical supply chain companies offered a sharp contrast to the broader retreat. McKesson Corporation announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032. Alongside the agreement, the company reaffirmed its annual earnings outlook, with McKesson Corporation pacing the sector's gainers. Fellow distributor Cencora Inc. followed higher in tandem.

Elsewhere in the sector, several pharmaceutical companies posted product and pipeline updates. Sanofi and Regeneron Pharmaceuticals expanded their long-standing antibody partnership, committing up to $8 billion to develop four new long-acting therapies. In clinical trials, Pfizer reported positive Phase 2 results for its experimental atopic dermatitis treatment, meeting primary endpoints for skin clearance. These positive pipeline milestones, however, were overshadowed by the broader rate-driven pressure across defensive groups.

At the close, XLV finished -1.3% at $166.19, during a session where 5 of the 11 sectors rose. The pullback leaves XLV at -3.2% over the past month. Over longer periods, the fund has maintained positive traction, standing +16.2% across the multi-month window and +15.8% over the past twelve months.